Selected publications

1. S. Best, P. Gubser, S. Sethumadhavan, A. Kersbergen, Y. Negrón Abril, J. Goldford, K. Sellers, W. Abeysekera, A. Garnham, J. McDonald, C. Weeden, D. Anderson, D. Pirman, T. Roddy, D. Creek, A. Kallies, G. Kingsbury, K. Sutherland. Glutaminase inhibition impairs CD8 T cell activation in STK11/Lkb1 deficient lung cancer. Cell Metab 2022. DOI: 10.1016/j.cmet.2022.04.003 Co-corresponding author. PMID: 35504291 
2. J. Hess, K. Sutherland and S. Best. (2021) Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. Transl Lung Cancer Res. 2021 Jun;10(6) 2788-2805 DOI:10.21037/tlcr-20-765 Senior and co-corresponding author PMID: 34295678
3. S. Best, C. Vandenberg, E. Abad, L. Whitehead, L. Guiu, S. Ding, M. Brennan, A. Strasser, M. Herold, K. Sutherland, A. Janic. Consequences of Zmat3 loss in C-MYC and mutant KRAS-driven tumorigenesis. Cell Death Dis. 2020 Oct 20;11(10):877. DOI: 10.1038/s41419-020-03066-9 PMID: 33082333
4. S. Best*, J. Hess*, F. Souza-Fonseca-Guimaraes, J. Cursons, A. Kersbergen, X. Dong, J. Rautela, S. Hyslop, M. Ritchie, M. Davis, T. Leong, L. Irving, D. Steinfort, N. Huntington, K. Sutherland. Harnessing natural killer immunity in metastatic small cell lung cancer. J Thorac Oncol. 2020 Sep;15(9):1507-1521. DOI: 10.1016/j.jtho.2020.05.008 PMID: 32470639
5. S. Best, S. Ding, A. Kersbergen, X. Dong, J.Y. Song, Y. Xie, B. Reljic, K. Li, J. Vince, V. Rathi, G. Wright, M. Ritchie, K. Sutherland. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nat Commun. 2019 Sep 13;10(1):4190. DOI: 10.1038/s41467-019-12164-y PMID: 31519898
6. S. Best*, C. Harapas*, A. Kersbergen, V. Rathi, M.L. Asselin-Labat, K. Sutherland. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. Oncogene. 2018 Nov;37(46):6096-6104 *These authors contributed equally. DOI: 10.1038/s41388-018-0399-5 PMID: 29991799
7. S. Best and K. Sutherland. “KEAPing” a lid on lung cancer: the Keap1-Nrf2 pathway. Cell Cycle. 2018;17(14):1696-1707 DOI: 10.1080/15384101.2018.1496756 PMID: 30009666
8. S. Best, D. DeSouza, A. Kersbergen, A. Policheni, S. Dayalan, D. Tull, V. Rathi, D. Gray, M. Ritchie, M. McConville, K. Sutherland. Synergy between the KEAP1/NRF2 and PI3K pathway drives non-small cell lung cancer with an altered immune microenvironment. Cell Metab. 2018 Apr 3;27(4):935-943.e4 DOI: 10.1016/j.cmet.2018.02.006 PMID: 29526543
9. S. Best, A. Kersbergen, M.L Asselin-Labat, K. Sutherland. Combining cell type-restricted adenoviral targeting with immunostaining and flow cytometry to identify cells-of-origin of lung cancer. Methods Mol Biol. 2018;1725:15-29 DOI: 10.1007/978-1-4939-7568-6_2 PMID: 29322405
10. S. Best, A. Nwaobasi, C. Schmults, M. Ramsey (2017) CCAR2 is required for proliferation and tumour maintenance in human Squamous Cell Carcinoma. J Invest Dermatol. 2017 Feb;137(2):506-512. DOI: 10.1016/j.jid.2016.09.027 PMID: 27725203

Further publications